These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17229768)

  • 1. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
    Lorusso D; Di Stefano A; Carone V; Fagotti A; Pisconti S; Scambia G
    Ann Oncol; 2007 Jul; 18(7):1159-64. PubMed ID: 17229768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
    Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
    Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
    Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
    Lopez AM; Wallace L; Dorr RT; Koff M; Hersh EM; Alberts DS
    Cancer Chemother Pharmacol; 1999; 44(4):303-6. PubMed ID: 10447577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
    Templeton AJ; Ribi K; Surber C; Sun H; Hsu Schmitz SF; Beyeler M; Dietrich D; Borner M; Winkler A; Müller A; von Rohr L; Winterhalder RC; Rochlitz C; von Moos R; Zaman K; Thürlimann BJ; Ruhstaller T;
    Breast; 2014 Jun; 23(3):244-9. PubMed ID: 24656636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
    Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
    Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
    Kanis M; Kesterson JP; Lele S
    Eur J Gynaecol Oncol; 2009; 30(4):387-8. PubMed ID: 19761128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
    Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
    Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®).
    Jung S; Sehouli J; Chekerov R; Kluschke F; Patzelt A; Fuss H; Knorr F; Lademann J
    Support Care Cancer; 2017 Nov; 25(11):3545-3549. PubMed ID: 28653108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy.
    Lademann J; Martschick A; Kluschke F; Richter H; Fluhr JW; Patzelt A; Jung S; Chekerov R; Darvin ME; Haas N; Sterry W; Zastrow L; Sehouli J
    Skin Pharmacol Physiol; 2014; 27(2):66-70. PubMed ID: 23969763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
    Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised controlled feasibility trial to evaluate Lawsonia inermis (henna)'s effect on palmar-plantar erythrodysesthesia induced by capecitabine or pegylated liposomal doxorubicin.
    Stavrinou M; Tsitsi T; Astras G; Paikousis L; Charalambous A
    Eur J Oncol Nurs; 2021 Apr; 51():101908. PubMed ID: 33626423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.
    Mangili G; Petrone M; Gentile C; De Marzi P; Viganò R; Rabaiotti E
    Gynecol Oncol; 2008 Feb; 108(2):332-5. PubMed ID: 18083217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.
    Julius JM; Tanyi JL; Nogueras-Gonzalez GM; Watkins JL; Coleman RL; Wolf JK; Smith JA
    Int J Gynecol Cancer; 2013 Feb; 23(2):348-54. PubMed ID: 23295941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
    Sehouli J; Oskay-Ozcelik G; Kühne J; Stengel D; Hindenburg HJ; Klare P; Heinrich G; Schmalfeldt B; Mertens H; Camara O; Lichtenegger W;
    Ann Oncol; 2006 Jun; 17(6):957-61. PubMed ID: 16600975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.